Please enter exact key words
AVAILABLE PROJECTS
Program Indication Discovery Preclinical PhaseⅠ PhaseⅡ PhaseⅢ
CAR-T Therapy
GHR106-CAR-T Cancer
RP215-CAR-T Cancer
Antibody Therapy
Anti-Scg3 Therapeutic Antibody Diabetic Retinopathy
hGHR106 Cancer
RP215 Cancer
CD3XCD20 bsAb Lymphomas
Cl3hmAb Acquired immune deficiency syndrome
MUC1-Ab Acute myelocytic leukemia
LAG3-Ab Cancer
OX40-Ab Cancer
Recombinant Protein Therapy
P75NEURO Neurological diseases
P11 Type 2 diabetes
Angiocidin Acute Myeloid Leukemia
TT-173 Surgical bleeding and trauma
Oncolytic Virotherapy
RV-scFv-PDL1 Cancer
OV-FV-01 Cancer
Chemotherapy
Polyoxygenated cyclohexene compound 4 Pain
Fascin inhibitor Cancer
Mitochondrial uncoupling agent Nonalcoholic steatohepatitis
HBV capsid inhibitor Hepatitis B
KCNQ2/3 channel modulator Epilepsy
Resveratrol (micellar) Alzheimer’s disease
Inflammatory factor regulators Psoriasis
Cell Therapy
Double negative T cells Acute myelocytic leukemia
BCMA - CAR-T Multiple myeloma
ABOUT US

Protheragen’s business is growing rapidly after founded in Ronkonkoma, New York in 2009. More offices have been established at different locations across China and the US ever since. Our business has evolved from the initial intermediary service to encompass segments in equity investment and program incubation.

Protheragen’s business is growing rapidly after founded in Ronkonkoma, New York in 2009. More offices have been established at different locations across China and the US ever since.

Protheragen Inc.

2200 Smithtown Avenue, Room 1, Ronkonkoma,
NY 11779-7329, USA
Phone: 1-516-765-9461    Fax: 1-516-927-0118
Email: info@protheragen.com